X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Under the agreement, GSK has the rights to develop GSK5458448/SCY-078 (ibrexafungerp), a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.
Lead Product(s): Ibrexafungerp Citrate,Caspofungin
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK5458448
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $401.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement January 03, 2024
Details:
Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive candidiasis.
Lead Product(s): Ibrexafungerp Citrate,Caspofungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $593.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement June 21, 2023
Details:
Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Lead Product(s): Coenzyme Q10,Caspofungin
Therapeutic Area: Genetic Disease Product Name: Ubiquinone
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clarus
Deal Size: $40.8 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement September 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
